https://peptideprices.net/blog Original reporting, cited research, and market analysis from PeptidePrices. en-us Mon, 24 Aug 2026 12:00:00 GMT https://peptideprices.net/blog/bpc-157-for-dogs-tb-500-viral-trend https://peptideprices.net/blog/bpc-157-for-dogs-tb-500-viral-trend Mon, 24 Aug 2026 12:00:00 GMT Industry News Does BPC-157 work for dogs? Review beagle bioavailability, published canine doses, safety data, veterinary cases and where products are sold. https://peptideprices.net/blog/is-retatrutide-fda-approved-2026 https://peptideprices.net/blog/is-retatrutide-fda-approved-2026 Mon, 24 Aug 2026 12:00:00 GMT Industry News Is retatrutide FDA approved? Not yet. Follow Lilly's planned Q1 2027 submission timeline and the rise in search, testing and internal interest. https://peptideprices.net/blog/fda-research-peptide-warning-letters-storefront-census https://peptideprices.net/blog/fda-research-peptide-warning-letters-storefront-census Sun, 23 Aug 2026 12:00:00 GMT Industry News PeptidePrices reviewed 13 FDA research-peptide warning letters. Ten warned businesses still sell peptides through public or account-gated storefronts. https://peptideprices.net/blog/what-is-eloralintide-ly3841136 https://peptideprices.net/blog/what-is-eloralintide-ly3841136 Thu, 13 Aug 2026 12:00:00 GMT Research Roundup Eloralintide is Lilly's selective amylin agonist in Phase 3. Review its Phase 2 weight-loss results, side effects, mechanism, and research-market status. https://peptideprices.net/blog/ara-290-peptide-dosage-human-trials https://peptideprices.net/blog/ara-290-peptide-dosage-human-trials Tue, 11 Aug 2026 12:00:00 GMT Research Roundup ARA-290 human trials tested 2 mg IV and 1, 4, or 8 mg SC. See why 4 mg stood out, the nerve-repair evidence, FDA status, and live pricing. https://peptideprices.net/blog/retatrutide-expanded-access-2026 https://peptideprices.net/blog/retatrutide-expanded-access-2026 Tue, 04 Aug 2026 12:00:00 GMT Industry News Lilly is reviewing limited retatrutide expanded-access requests. See who may qualify, how physician requests work, and what remains unknown. https://peptideprices.net/blog/dsip-peptide-fda-vote-2026 https://peptideprices.net/blog/dsip-peptide-fda-vote-2026 Sat, 25 Jul 2026 12:00:00 GMT Research Roundup FDA advisers voted against adding DSIP peptide forms to the 503A Bulks List. See the vote, evidence gaps, and what the decision does not mean. https://peptideprices.net/blog/fda-pcac-bpc-157-kpv-tb-500-mots-c-vote-2026 https://peptideprices.net/blog/fda-pcac-bpc-157-kpv-tb-500-mots-c-vote-2026 Thu, 23 Jul 2026 12:00:00 GMT Research Roundup FDA's PCAC voted 8-6-1 to recommend BPC-157, KPV, TB-500, and MOTS-c for the 503A Bulks List. Learn what the advisory votes do and do not change. https://peptideprices.net/blog/klow-peptide-blend-evidence-risks https://peptideprices.net/blog/klow-peptide-blend-evidence-risks Tue, 21 Jul 2026 12:00:00 GMT Compound Deep-Dive KLOW combines GHK-Cu, BPC-157, TB-500, and KPV. Review what each ingredient is, what human studies show, and what the full blend has not proved. https://peptideprices.net/blog/glp-1-microdosing-evidence-cost https://peptideprices.net/blog/glp-1-microdosing-evidence-cost Tue, 21 Jul 2026 12:00:00 GMT GLP-1 / Weight Loss What does GLP-1 microdosing mean? Review the evidence, FDA-approved dose schedules, compounded-drug risks, advertised costs, and provider checks. https://peptideprices.net/blog/ghk-cu-skin-hair-injections-evidence https://peptideprices.net/blog/ghk-cu-skin-hair-injections-evidence Tue, 21 Jul 2026 12:00:00 GMT Compound Deep-Dive Does GHK-Cu help skin or hair? Compare human, animal, and laboratory evidence for topical copper peptides, hair claims, and injectable GHK-Cu. https://peptideprices.net/blog/peptides-for-womens-weight-loss https://peptideprices.net/blog/peptides-for-womens-weight-loss Fri, 17 Jul 2026 12:00:00 GMT Goal-Specific Guide Which weight-loss peptides have real evidence for women? Compare semaglutide, tirzepatide, compounded options, safety, and telehealth access. https://peptideprices.net/blog/peptides-for-women-over-40 https://peptideprices.net/blog/peptides-for-women-over-40 Thu, 16 Jul 2026 12:00:00 GMT Goal-Specific Guide An evidence-first guide to peptides for women over 40: weight management, skin, recovery, sexual health, menopause limits, and safety red flags. https://peptideprices.net/blog/peptideprices-chrome-extension-auto-coupons https://peptideprices.net/blog/peptideprices-chrome-extension-auto-coupons Tue, 14 Jul 2026 12:00:00 GMT Product Update Our free Chrome extension auto-applies PeptidePrices partner-vendor coupon codes at checkout, so you never miss a discount. No copy-pasting, no personal-data collection. Here is exactly what it does, how it works, and how to install it. https://peptideprices.net/blog/centenarian-immune-system-longevity https://peptideprices.net/blog/centenarian-immune-system-longevity Sat, 11 Jul 2026 12:00:00 GMT Research Roundup A 2026 Nature Reviews Immunology review maps how people who reach 100+ stay biologically young: lower NLRP3 inflammation, more autophagy, calmer cellular senescence, an intact gut barrier. The honest science, and where the longevity compounds people research fit, and don't. https://peptideprices.net/blog/bge-102-nlrp3-inhibitor-hscrp https://peptideprices.net/blog/bge-102-nlrp3-inhibitor-hscrp Thu, 25 Jun 2026 12:00:00 GMT Research Roundup BioAge's BGE-102, an oral NLRP3 inhibitor, drove ≥85% median hsCRP reductions in a Phase 1 obesity cohort. The honest read — the data, the CANTOS precedent, the crowded NLRP3 race, and what it means (and doesn't) for inflammaging. https://peptideprices.net/blog/aldh1a2-retinoic-acid-regeneration https://peptideprices.net/blog/aldh1a2-retinoic-acid-regeneration Tue, 23 Jun 2026 12:00:00 GMT Research Roundup In a 2025 Science study, scientists restored regenerative wound healing in mice by switching ALDH1A2 back on — the enzyme that makes retinoic acid. Here's the honest science, plenty of sources, and what it does (and doesn't) mean for healing. https://peptideprices.net/blog/ai-drug-discovery-insilico-peptides https://peptideprices.net/blog/ai-drug-discovery-insilico-peptides Sun, 21 Jun 2026 12:00:00 GMT Research Roundup A generative-AI-designed drug just published Phase 2a human data in Nature Medicine. Here's the honest breakdown of Insilico Medicine's rentosertib, what AlphaFold actually changed, how AI is being used to design new peptides — and why your semaglutide was not AI-designed. https://peptideprices.net/blog/how-to-verify-peptide-coa https://peptideprices.net/blog/how-to-verify-peptide-coa Sat, 20 Jun 2026 12:00:00 GMT Buyer's Guide How to verify a peptide COA: named lab, batch match, and lab-portal lookup. Use the free /coa-check tool. Not medical advice. https://peptideprices.net/blog/glp1-gene-therapy-fractyl-rejuva https://peptideprices.net/blog/glp1-gene-therapy-fractyl-rejuva Fri, 19 Jun 2026 12:00:00 GMT Research Roundup Fractyl's Rejuva (RJVA-001) is an experimental AAV gene therapy designed to make your own pancreas produce GLP-1 — a potential one-time alternative to weekly semaglutide. The mechanism, the preclinical data, the May 2026 first-in-human authorization, and the honest caveats about a treatment you can't undo. https://peptideprices.net/blog/peptide-fulfillment-rapidfulfillment-partner https://peptideprices.net/blog/peptide-fulfillment-rapidfulfillment-partner Thu, 18 Jun 2026 12:00:00 GMT Partner Resource RapidFulfillment is PeptidePrices' fulfillment and cold-chain logistics partner for research peptide brands — RUO peptide fulfillment, white-label dropshipping, and cold-chain logistics. Mention PeptidePrices for $300 off your fulfillment deposit. https://peptideprices.net/blog/rls-1496-gpx4-senescent-skin https://peptideprices.net/blog/rls-1496-gpx4-senescent-skin Wed, 17 Jun 2026 12:00:00 GMT Research Roundup RLS-1496 is Rubedo Life Sciences' first-in-class topical GPX4 modulator — a cream designed to clear senescent 'zombie' skin cells via ferroptosis. The Phase 1 and Phase 1b/2a data across psoriasis, atopic dermatitis, photoaging and actinic keratosis (a company-reported 46% lesion drop in 4 weeks), the 'senoadaptive' thesis, and the honest caveats. https://peptideprices.net/blog/verve-102-gene-editing-cholesterol https://peptideprices.net/blog/verve-102-gene-editing-cholesterol Fri, 12 Jun 2026 12:00:00 GMT Research Roundup VERVE-102 is a single-infusion gene-editing therapy that permanently switches off the PCSK9 gene to lower LDL cholesterol. The Heart-2 trial data, the VERVE-101 safety scare, the $1.3B Lilly buyout, and the honest caveats about a treatment you can't undo. https://peptideprices.net/blog/ada-2026-glp1-pipeline-roundup https://peptideprices.net/blog/ada-2026-glp1-pipeline-roundup Tue, 09 Jun 2026 12:00:00 GMT GLP-1 / Weight Loss The ADA's 86th Scientific Sessions (June 5–8, 2026) dumped the year's biggest GLP-1 data: retatrutide's ~28% weight loss, CagriSema's first diabetes trials, and orforglipron's oral readout. A plain-English roundup — including the caveats. https://peptideprices.net/blog/bpc-157-human-evidence-reality-check https://peptideprices.net/blog/bpc-157-human-evidence-reality-check Tue, 09 Jun 2026 12:00:00 GMT Compound Deep-Dive BPC-157 has a huge, impressive animal-research literature and almost no human-trial data. Both are true. Here's exactly what's been published in people — the PL-14736 program, the registered-but-unpublished trial — and why the gap matters. https://peptideprices.net/blog/ss-31-elamipretide-mitochondrial-peptide https://peptideprices.net/blog/ss-31-elamipretide-mitochondrial-peptide Tue, 09 Jun 2026 12:00:00 GMT Compound Deep-Dive On Sept 19, 2025, SS-31 became FORZINITY — the first FDA-approved drug to directly target the mitochondria. But the approval is for an ultra-rare disease, and the broad anti-aging story is messier than the headline. What the cardiolipin-binding peptide actually does, and doesn't. https://peptideprices.net/blog/glp1-beyond-weight-loss-new-indications https://peptideprices.net/blog/glp1-beyond-weight-loss-new-indications Tue, 09 Jun 2026 12:00:00 GMT GLP-1 / Weight Loss GLP-1s are no longer just diabetes and weight-loss drugs. A clear-eyed map of what's actually FDA-approved (heart, sleep apnea, MASH), what has strong trial data (kidney), and what has failed or is still hype (Alzheimer's, addiction). https://peptideprices.net/blog/enlicitide-explained https://peptideprices.net/blog/enlicitide-explained Mon, 08 Jun 2026 12:00:00 GMT Research Roundup Enlicitide (Merck's former MK-0616) is a once-daily cholesterol pill that's really an oral macrocyclic peptide — engineered to survive the gut. The Phase 3 CORALreef data, the empty-stomach catch, and what it signals for oral peptide drugs. https://peptideprices.net/blog/fda-peptide-hearing-july-2026 https://peptideprices.net/blog/fda-peptide-hearing-july-2026 Wed, 03 Jun 2026 12:00:00 GMT Research Roundup On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviews 7 peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) for the 503A compounding list, with 5 more by early 2027. Here's what the hearing means, and what it doesn't. https://peptideprices.net/blog/orforglipron-first-oral-glp1-pill https://peptideprices.net/blog/orforglipron-first-oral-glp1-pill Wed, 03 Jun 2026 12:00:00 GMT Research Roundup Orforglipron (Foundayo) is the first oral GLP-1 approved for weight loss, and, surprisingly, it's a non-peptide small molecule, not a peptide. Here's how it works, the ATTAIN trial numbers, and how it stacks up against injectable semaglutide and tirzepatide. https://peptideprices.net/blog/peptide-skeptics-what-the-critics-agree-on https://peptideprices.net/blog/peptide-skeptics-what-the-critics-agree-on Wed, 03 Jun 2026 12:00:00 GMT Research Roundup Three credible voices, cardiologist Eric Topol, Peter Attia, and Paul Saladino, have pushed back on the peptide boom. Here's where they actually converge: the human-trial evidence gap, the GLP-1 exception, and the gray-market quality problem. https://peptideprices.net/blog/paul-saladino-peptides-no-free-lunch https://peptideprices.net/blog/paul-saladino-peptides-no-free-lunch Wed, 03 Jun 2026 12:00:00 GMT Research Roundup Dr. Paul Saladino's YouTube breakdown of peptides, GLP-1s, BPC-157/TB-500, GH secretagogues, melanotan, sorted into what's effective, what's risky, and why he argues there's no biological free lunch. We separate his verifiable points from his strong opinions. https://peptideprices.net/blog/huberman-peptides-podcast-abud-bakri https://peptideprices.net/blog/huberman-peptides-podcast-abud-bakri Mon, 01 Jun 2026 12:00:00 GMT Research Roundup A clear, fact-checked breakdown of the Huberman Lab peptides episode with Dr. Abud Bakri — BPC-157, GLP-1s, the Russian bioregulators, the thymus, GH secretagogues, and the gray-market reality. We separate the established science from the anecdotes. https://peptideprices.net/blog/retatrutide-drug-or-biologic-fda-classification-fight https://peptideprices.net/blog/retatrutide-drug-or-biologic-fda-classification-fight Sun, 24 May 2026 12:00:00 GMT Research Roundup Eli Lilly is fighting the FDA over whether retatrutide is a small-molecule drug or a biologic, a distinction that turns on amino-acid counting and could reshape competition, compounding, and the obesity-drug market. Here's what's actually at stake. https://peptideprices.net/blog/best-peptides-for-joint-pain-2026 https://peptideprices.net/blog/best-peptides-for-joint-pain-2026 Sun, 26 Apr 2026 12:00:00 GMT Recovery & Joint Health Looking at peptides for joint pain or tendon recovery? We rank the 7 most-researched options by evidence quality, side-effect profile, and current 2026 vendor pricing. https://peptideprices.net/blog/how-to-vet-peptide-vendor-checklist https://peptideprices.net/blog/how-to-vet-peptide-vendor-checklist Wed, 22 Apr 2026 12:00:00 GMT Buyer Guide Six concrete criteria for checking whether a peptide vendor is trustworthy — named labs, batch COAs, endotoxin, address, track record, reviews.